ProQR Therapeutics NV
NASDAQ:PRQR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ProQR Therapeutics NV
Revenue
ProQR Therapeutics NV
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Revenue
€16.3m
|
CAGR 3-Years
50%
|
CAGR 5-Years
12%
|
CAGR 10-Years
18%
|
|
|
Pharming Group NV
AEX:PHARM
|
Revenue
$376.1m
|
CAGR 3-Years
22%
|
CAGR 5-Years
12%
|
CAGR 10-Years
43%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Revenue
$16.1m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
4%
|
|
|
argenx SE
XBRU:ARGX
|
Revenue
$4.2B
|
CAGR 3-Years
116%
|
CAGR 5-Years
152%
|
CAGR 10-Years
88%
|
|
|
Merus NV
NASDAQ:MRUS
|
Revenue
$56.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
15%
|
CAGR 10-Years
36%
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Revenue
$12m
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ProQR Therapeutics NV
Glance View
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. The company is headquartered in Leiden, Zuid-Holland. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
See Also
What is ProQR Therapeutics NV's Revenue?
Revenue
16.3m
EUR
Based on the financial report for Dec 31, 2025, ProQR Therapeutics NV's Revenue amounts to 16.3m EUR.
What is ProQR Therapeutics NV's Revenue growth rate?
Revenue CAGR 10Y
18%
Over the last year, the Revenue growth was -16%. The average annual Revenue growth rates for ProQR Therapeutics NV have been 50% over the past three years , 12% over the past five years , and 18% over the past ten years .
